BRIEF published on 03/10/2026 at 09:05, 7 months 7 days ago GenSight Biologics lève 1,7 million d'euros lors d'une nouvelle levée de fonds. Stratégie Financière Essais Cliniques Thérapie Génique Collecte De Fonds Actions Et Bons De Souscription
BRIEF published on 03/10/2026 at 09:05, 7 months 7 days ago GenSight Biologics Secures €1.7 Million in Fresh Fundraising Fundraising Clinical Trials Gene Therapy Financial Strategy Shares And Warrants
PRESS RELEASE published on 03/10/2026 at 09:00, 7 months 7 days ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics réalise une levée de fonds de près de 1,7 million d'euros pour développer des thérapies géniques innovantes. Annonce de succès pour l'opération Biopharmaceutique Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
PRESS RELEASE published on 03/10/2026 at 09:00, 7 months 7 days ago Inside Information / News release on accounts, results GenSight Biologics successfully raises nearly €1.7 million, continuing its fundraising activities for gene therapies. Company's CEO and CFO comment on operational milestones and future plans Fundraising GenSight Biologics Gene Therapies Cash Runway Operational Milestones
BRIEF published on 03/09/2026 at 07:35, 7 months 8 days ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
BRIEF published on 03/09/2026 at 07:35, 7 months 8 days ago GenSight Biologics : Point sur les Programmes d'Accès Précoce et l'Étude REVISE Thérapie Génique GenSight Biologics Neuropathie Optique Étude REVISE Accès Précoce
BRIEF published on 03/09/2026 at 07:35, 7 months 8 days ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
BRIEF published on 03/09/2026 at 07:35, 7 months 8 days ago GenSight Biologics fait le point sur ses programmes d'accès précoce et l'étude REVISE GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ® Étude REVISER Programmes D'accès Anticipé
PRESS RELEASE published on 03/09/2026 at 07:30, 7 months 8 days ago Informations privilégiées / Autres communiqués GenSight Biologics fait le point sur les programmes d'accès précoce de GS010/LUMEVOQ et sur l'étude REVISE en cours, avec des approbations en France, Israël et aux États-Unis Thérapie Génique GenSight Biologics GS010/LUMEVOQ Accès Précoce Dose REVISE
PRESS RELEASE published on 03/09/2026 at 07:30, 7 months 8 days ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
Published on 10/17/2026 at 03:20, 15 hours 22 minutes ago Battery X Metals Highlights Participation at X Takeover 2026, an Electric Vehicle and Emerging Technology Event Held at Tesla's Gigafactory Texas, Providing Exposure to Industry Perspectives and Technology Developments
Published on 10/17/2026 at 03:15, 15 hours 27 minutes ago Vanta Closes Second Tranche of Private Placement Financing and Welcomes Launch of First U.S.-Listed Peptide ETF, Highlighting Growing Recognition of Peptide Industry
Published on 10/16/2026 at 23:35, 19 hours 7 minutes ago Initial Closing of US$3.4 Million Private Placement
Published on 10/16/2026 at 23:30, 19 hours 12 minutes ago NiobiumX Mining Inc. Announces Retraction of Recent Marketing Materials
Published on 10/16/2026 at 23:00, 19 hours 42 minutes ago Grid Announces Adoption of Advance Notice By-Law and Provides Shareholder Meeting Update
Published on 10/17/2026 at 18:00, 42 minutes ago Baader Bank announces extended trading hours 23 hours a day starting Q1/2027
Published on 10/17/2026 at 13:05, 5 hours 37 minutes ago Luong Quoi Coconut Vietnam to Showcase Vietnamese Coconut Expertise at SIAL Paris 2026
Published on 10/17/2026 at 12:50, 5 hours 52 minutes ago AGFUND wins international award for excellence in inclusive banking and social impact
Published on 10/16/2026 at 20:08, 22 hours 34 minutes ago EQS-Adhoc: Rath AG // Rath Group reaches agreement with its key financial creditors on the terms of a transformation agreement and launches a transformation programme
Published on 10/16/2026 at 19:20, 23 hours 22 minutes ago Arity to Acquire INRIX, Advancing a Connected Vision for the Future of Transportation
Published on 10/16/2026 at 19:54, 22 hours 48 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 30 septembre 2026
Published on 10/16/2026 at 18:48, 23 hours 54 minutes ago Disclosure of transactions in own shares from October 12 to October 16, 2026
Published on 10/16/2026 at 18:48, 23 hours 54 minutes ago Déclaration hebdomadaire d'opérations effectuées du 12 au 16 octobre 2026
